Ironwood Pharmaceuticals Reports Second Quarter 2022 Results; Maintains Full Year Guidance Due to Continued Strength of LINZESS® Prescription Demand
Go back to Ironwood Pharmaceuticals Reports Second Quarter 2022 Results; Maintains Full Year Guidance Due to Continued Strength of LINZESS® Prescription Demand| IRONWOOD PHARMA-A (NASDAQ: IRWD) | Delayed: 3.82 +0.28 (7.91%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.54 | 52 Week High | $16.89 | |||
| Open | $3.60 | 52 Week Low | $7.35 | |||
| Day High | $3.91 | P/E | N/A | |||
| Day Low | $3.57 | EPS | $-2.35 | |||
| Volume | 2,522,919 | |||||
